ALK Sets High Bar for 2025 Report Amid Strategic Wins

HØRSHOLM, Denmark – February 13, 2026 – Global allergy-focused pharmaceutical company ALK is poised to reveal its full-year financial results for 2025 on Friday, February 20, setting the stage for a highly anticipated update for investors and the broader healthcare market. The announcement will be followed by a presentation where President & CEO Peter Halling and his management team will detail the year's performance and provide an outlook for the future.

The upcoming report follows a year marked by robust financial momentum, significant pipeline advancements, and pivotal strategic partnerships designed to expand the company's global footprint. Having already raised its financial guidance mid-year, expectations are high for ALK to confirm a year of substantial growth and outline its path forward in a dynamic allergy treatment landscape.

A Year of Robust Financial Health

Investors will be looking for confirmation of the strong growth trajectory ALK established throughout 2025. The company's third-quarter results provided a powerful indicator of its performance, showcasing an 18% revenue growth and a remarkable 41% increase in earnings in local currencies. This led ALK to upgrade its full-year forecast, projecting revenue growth of 13-15% and an impressive EBIT margin of approximately 26%, up from a previous estimate of 25%.

This performance has been underpinned by strong sales of its core allergy immunotherapy (AIT) tablets and anaphylaxis products. For the first nine months of 2025, revenue surpassed DKK 4.5 billion, with a gross margin improvement to 67%, driven by higher volumes and a favorable product mix, particularly from European tablet sales. The company's financial discipline was also evident in its balance sheet, which showed a negative net debt-to-EBITDA ratio, signaling a debt-free position that provides significant flexibility for future investments.

This financial strength has resonated with market analysts, who largely hold a "Buy" or "Outperform" consensus rating for the company's stock. Following the strong Q3 performance, several analysts became more bullish, with the consensus price target rising to DKK 219 and some projections reaching as high as DKK 255. The upcoming report will be scrutinized to see if the full-year results justify this optimism and support forecasts of continued double-digit earnings and revenue growth.

Strategic Expansion and Key Partnerships

Beyond the balance sheet, 2025 was a landmark year for ALK's long-term strategy, defined by two major international partnerships. In September, the company announced a strategic alliance with Chinese biopharmaceutical firm GenSci to develop and commercialize its house dust mite (HDM) AIT products, ACARIZAX® and Alutard®, in China. The deal, which includes an upfront payment of approximately DKK 245 million and potential milestones of up to DKK 1.3 billion, is set to significantly accelerate ALK's entry and uptake in one of the world's largest and fastest-growing healthcare markets.

In North America, ALK expanded its commercial reach through a co-promotion agreement with ARS Pharmaceuticals for neffy, a needle-free epinephrine nasal spray for severe allergic reactions. The partnership, announced in May 2025, allows ALK to promote the product to thousands of pediatricians across the U.S., complementing ARS Pharma's own promotional efforts and expanding access to this critical emergency treatment ahead of the key back-to-school season.

These moves are central to ALK's overarching "Allergy+" strategy, which aims to maximize the value of its existing portfolio while diversifying into adjacent areas like food allergies and anaphylaxis. The focus on geographic expansion, particularly in China and the U.S., is expected to be a key driver of future growth.

Pipeline Progress and Innovation in Allergy Care

ALK's R&D engine was also highly productive in 2025, delivering crucial advancements that bolster its future product pipeline. The company successfully rolled out pediatric versions of its HDM and tree pollen SLIT-tablets, ACARIZAX and ITULAZAX, with market response reportedly exceeding initial expectations. These launches, supported by new approvals in Europe and Canada for pediatric use, significantly expand the addressable patient population for ALK's flagship tablet franchise.

Progress was also made in new treatment areas. The European launch of EURneffy began in Germany in late June, with further rollouts planned for other key markets like the UK. This marks ALK's entry into the emergency treatment space with a highly anticipated needle-free alternative to auto-injectors.

Looking further ahead, the company's food allergy program achieved a key milestone by completing patient recruitment for its Phase 2 trial of a peanut allergy SLIT-tablet ahead of schedule. This positions ALK to become a significant player in the high-need area of food allergy treatments. The initiation of a Phase 3 bridging trial for ACARIZAX in China further supports its strategic ambitions in the region.

Navigating a Dynamic Global Allergy Market

The company's strong performance in 2025 occurred against the backdrop of a resurgent global allergy market. After a flat period, the market grew by 3.0% in the year to mid-2025 and was valued at nearly USD 23 billion. Projections indicate it could reach over USD 35 billion by 2031, fueled by rising allergy prevalence, climate-related factors, and the introduction of breakthrough biologic therapies.

A key trend benefiting ALK is the increasing shift toward home-based sublingual immunotherapy (SLIT), where the company is a market leader with its tablet portfolio. This growing patient and physician preference for the convenience and safety of SLIT regimens over traditional injections is a powerful tailwind for ALK's core business.

The market is not without its competitive pressures, as new biologics and other novel treatments for severe allergies gain traction. However, ALK's focused strategy on AIT, its expanding pediatric indications, and its diversification into food allergy and anaphylaxis position it well to navigate this evolving landscape. The February 20th presentation will provide the definitive scorecard on how these strategic initiatives translated into full-year performance and what they signal for the company's trajectory in the expanding global allergy care market.